TP53 and neoplasm: Patients with TNBC tumors frequently fail standard chemotherapy, and although recent attempts at treatment with PARP inhibitors, PI3K inhibitors and modulators of the p53 family members have shown some early promise [33], no clinically validated drug target exist that are effective as neo-adjuvant or adjuvant therapy and frequently the tumor relapses locally, regionally or as systemic metastases.